MGX · Metagenomi Therapeutics, Inc.
Market Cap
$44.95M
Shares
37.78M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.18
Open$1.18
Day$1.17–1.19
52W close$1.14–3.35
Avg vol 30d139K
Short int1.5M · 3.8% float · 11.0d
Short vol26%
Last earningsNov 12, 2025
DataFeb 2024–Aug 2026
Filing10-Q · Aug 10
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 10, 2026
Equibles Rating
blended score · not investment adviceOverall
Strong Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Poor
Quant / Vol
Very High
Market backdrop
VIX 14.9 · calm
Equity put/call 0.70
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−18%
below
Price vs 50-day avg
−4%
below
RSI (14)
41
neutral
MACD trend
Negative
52-week position
2%
near low
Momentum
relative strength
1-month return
−2%
trailing
6-month return
−33%
trailing
YTD return
−27%
this year
Relative strength
−46%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +4 funds added
Insider flow
Distributing
Net -$9.3K over 90 days · 100% sells
Short interest
Falling
3.85% of float · ▼ -2.7% MoM · 11.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
43 holders — near 2-yr low, contrarian setup
Squeeze score
58
elevated · 0–100
Fundamentals
Revenue growth
−52%
Y/Y
EPS growth
0%
Y/Y
Free cash flow
$-89.5M
Quant / Vol
risk profile
Volatility
64%
annualized · 1-yr
Max drawdown
−66%
past year
ATR
3.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−18%
Bearish
Price vs 50-day avg
−4%
Neutral
RSI (14)
41
Neutral
MACD trend
Negative
Bearish
52-week position
2%
Bearish
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow
Distributing
-10% holders QoQ · +4 funds added
Insider flow
Distributing
Net -$9.3K over 90 days · 100% sells
Short interest
Falling
3.85% of float · ▼ -2.7% MoM · 11.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
43 holders — near 2-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1
Now $1 · 2%
Range high $3
vs 200-day avg -18%
vs 50-day avg -4%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MGX
this stock
Metagenomi Therapeutics, Inc.
|
$44.95M | -27.2% | -51.8% | — | 3.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$137.30B | +20.1% | +46.2% | 31.6 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.77B | +3.5% | +20.8% | 19.7 | 2.3% |
|
ARGX
Argenx SE
|
$64.16B | +22.7% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.23B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MGX | -2.5% | -2.5% | -33.0% | -0.8% | -27.2% |
| SPY | +0.5% | +1.2% | +13.3% | +2.7% | +12.5% |
| vs SPY | -3.0% | -3.7% | -46.2% | -3.5% | -39.6% |
Key facts
CIK
1785279
CUSIP
59102M104
13F (30d)
40 filings
40 filers
Visit website
Investor relations